MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
National Research Corporation Cash Conversion Cycle 2011-2026 | NRC
Annual Cash Conversion Cycle National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 | 29.9 | 33 | 33.9 | 34.1 | 35 | 23.3 | 32.7 | 42.7 | 35.3 | 35.6 | 31.1 | 43.5 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 43.5 | 23.3 | 33.8 |
Quarterly Cash Conversion Cycle National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.2 | 31.8 | 30.4 | - | 26.9 | - | - | - | 31.7 | 32.9 | 35.9 | - | 18.6 | 19.5 | 35.2 | - | 36.8 | 35.6 | 36.3 | - | 38 | 40.8 | 34.4 | - | 32.7 | 33.8 | 34.1 | - | 36.2 | 38.8 | 39.3 | - | 46.7 | 47.5 | 38.7 | - | 36.7 | 38 | 33.8 | - | 35.5 | 36.6 | 31.1 | - | 31.3 | 30.9 | 33.6 | - | 45 | 45.1 | 42.4 | - | 51.7 | 53.6 | 47.5 | - | 55 | 55.7 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 | 18.6 | 37.4 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
111 | $ 110.28 | -2.82 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
42.5 | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
33.5 | $ 13.21 | -2.44 % | $ 3.75 B | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 14.31 | -2.02 % | $ 1.86 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
149 | $ 16.41 | -11.3 % | $ 177 M |  China |
 |
BioNano Genomics
BNGO
|
166 | $ 1.15 | -0.43 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
224 | $ 9.03 | -2.48 % | $ 602 M | USA |
 |
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
134 | $ 62.84 | -4.93 % | $ 24.5 B | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 15.54 | -5.13 % | $ 470 M | USA |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
79.6 | $ 84.0 | -4.65 % | $ 10.5 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 24.0 | -2.83 % | $ 667 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 158.89 | -3.78 % | $ 7.88 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 195.64 | -1.27 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
-82.8 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
115 | $ 8.45 | - | $ 33.7 M |  Israel |
 |
ICON Public Limited Company
ICLR
|
62 | $ 102.3 | -0.76 % | $ 8.44 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
103 | $ 561.97 | -1.98 % | $ 45.2 B | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
142 | $ 117.62 | -5.45 % | $ 18.7 B | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
44.9 | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 452.91 | -2.94 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 233.1 | -2.91 % | $ 25.4 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
49.3 | $ 4.38 | -5.19 % | $ 406 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-1.24 K | $ 4.26 | -7.19 % | $ 2.29 M | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 7.35 | -5.28 % | $ 942 M | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 164.54 | -2.87 % | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Natera
NTRA
|
81.5 | $ 184.45 | -5.96 % | $ 18.2 B | USA |
 |
OPKO Health
OPK
|
242 | $ 1.15 | -1.79 % | $ 798 M | USA |